Aignostics
Aignostics is an AI-powered company transforming drug development and improving patient outcomes through precision medicine. They offer a range of products including Foundation Models and the Atlas H&E-TME profiling application, supported by custom services for target and biomarker discovery, translational research, and digital diagnostics. The company emphasizes its deep biomedical expertise, advanced machine learning capabilities, and collaborations with academic institutions. Aignostics, a spin-off from Charité Berlin, has offices in Berlin and New York, and is certified with ISO 13485 and 27001, with a GCP-ready clinical trial platform. They have raised $55 million in funding and employ over 120 people.
Aignostics
Aignostics is an AI-powered company transforming drug development and improving patient outcomes through precision medicine. They offer a range of products including Foundation Models and the Atlas H&E-TME profiling application, supported by custom services for target and biomarker discovery, translational research, and digital diagnostics. The company emphasizes its deep biomedical expertise, advanced machine learning capabilities, and collaborations with academic institutions. Aignostics, a spin-off from Charité Berlin, has offices in Berlin and New York, and is certified with ISO 13485 and 27001, with a GCP-ready clinical trial platform. They have raised $55 million in funding and employ over 120 people.
